Please wait while the formulary information is being retrieved.
PIFELTRO (doravirine)
- HIV infection
100 mg tablet
- 1 tablet (100 mg) by oral route once daily at the same time eachday
HIV infection
- 1 tablet (100 mg) by oral route once daily at the same time eachday
- 1 tablet (100 mg) by oral route 2 times per day at the same times each day when taken with rifabutin
- None
Contraindicated
- None
Severe
Moderate
- None
- Lactating mother
Contraindicated
- None
Severe
Moderate
- None
PIFELTRO (doravirine)
- HIV infection
- None
- Acute abdominal pain
- Diarrhea
- Dizziness
- Dream disorder
- Fatigue
- Headache disorder
- Nausea
More Frequent
Severe
Less Severe
- Hyperbilirubinemia
- Increased alanine transaminase
- Increased aspartate transaminase
- Altered consciousness
- Drowsy
- Lethargy
- Skin rash
- Syncope
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Autoimmune hepatitis
- Graves' disease
- Guillain-barre syndrome
- Polymyositis
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Doravirine
No pediatric safety and efficacy established.
- 1 Day – 18 Years
- No pediatric safety and efficacy established.
Doravirine
- Severity Level:
2
- Additional Notes: Insufficient human data available.
Contraindicated
Doravirine
Cdc does not rec breastfeeding in hiv-1- infected mothers
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Cdc does not rec breastfeeding in hiv-1- infected mothers |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| HIV infection | |
| B20 | Human immunodeficiency virus [HIv] disease |
| B97.35 | Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere |
| O98.7 | Human immunodeficiency virus [HIv] disease complicating pregnancy, childbirth and the puerperium |
| O98.71 | Human immunodeficiency virus [HIv] disease complicating pregnancy |
| O98.711 | Human immunodeficiency virus [HIv] disease complicating pregnancy, first trimester |
| O98.712 | Human immunodeficiency virus [HIv] disease complicating pregnancy, second trimester |
| O98.713 | Human immunodeficiency virus [HIv] disease complicating pregnancy, third trimester |
| O98.719 | Human immunodeficiency virus [HIv] disease complicating pregnancy, unspecified trimester |
| O98.72 | Human immunodeficiency virus [HIv] disease complicating childbirth |
| O98.73 | Human immunodeficiency virus [HIv] disease complicating the puerperium |
| Z21 | Asymptomatic human immunodeficiency virus [HIv] infection status |
| 0-9 | A-Z |
|---|---|
| B20 | Human immunodeficiency virus [HIv] disease |
| B97.35 | Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere |
| O98.7 | Human immunodeficiency virus [HIv] disease complicating pregnancy, childbirth and the puerperium |
| O98.71 | Human immunodeficiency virus [HIv] disease complicating pregnancy |
| O98.711 | Human immunodeficiency virus [HIv] disease complicating pregnancy, first trimester |
| O98.712 | Human immunodeficiency virus [HIv] disease complicating pregnancy, second trimester |
| O98.713 | Human immunodeficiency virus [HIv] disease complicating pregnancy, third trimester |
| O98.719 | Human immunodeficiency virus [HIv] disease complicating pregnancy, unspecified trimester |
| O98.72 | Human immunodeficiency virus [HIv] disease complicating childbirth |
| O98.73 | Human immunodeficiency virus [HIv] disease complicating the puerperium |
| Z21 | Asymptomatic human immunodeficiency virus [HIv] infection status |
Formulary Reference Tool